Glucokinase Activators are a set of chemical compounds that directly or indirectly catalyze the activation of Glucokinase, a key enzyme regulating glucose metabolism in the liver and pancreatic β-cells. Glucose, the natural substrate of Glucokinase, directly enhances its activity through allosteric activation, increasing the enzyme's affinity for glucose and facilitating the phosphorylation of glucose to glucose-6-phosphate, a critical step for glycolysis and glycogen synthesis. Glucosamine and Mannose, as alternative hexose substrates, can also enhance Glucokinase activity by similar allosteric mechanisms. Fructose and Sorbitol act indirectly; the metabolism of these sugars alters the levels of ATP and ADP within the cell, with ADP acting as an allosteric activator of Glucokinase.
BC026682 activators comprise a chemical class that can enhance the activity of the molecular target denoted as BC026682. The discovery process for these activators typically begins with a high-throughput screening (HTS) strategy, where vast compound libraries are methodically tested for their effect on BC026682 activity. The assays used in HTS are designed to provide a quantitative measure of BC026682 activation, often through the employment of colorimetric, fluorescent, or luminescent reporters that directly correlate with the activity of the target. Compounds that demonstrate an ability to upregulate BC026682 activity are flagged for further validation. The subsequent validation phase involves secondary assays, which are more refined and specific than the initial screening. These assays are intended to confirm the activity of the compounds and to rule out non-specific effects or experimental artifacts. They are critically important for verifying that the identified compounds are true activators of BC026682.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate and activate "BC026682" if it is a substrate of PKC or is involved in PKC-regulated pathways. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium levels and potentially activating calcium-dependent kinases that could phosphorylate and activate "BC026682." | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors, potentially resulting in downstream signaling events that lead to the activation of "BC026682" through G-protein coupled receptor pathways. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $106.00 $166.00 $289.00 $550.00 $819.00 | 2 | |
As a cAMP analog, 8-Bromo-cAMP activates PKA, potentially leading to the phosphorylation and activation of "BC026682" if it is a PKA substrate. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels of proteins, which could include "BC026682," thereby enhancing its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as a calcium ionophore and could increase intracellular calcium, potentially activating calcium-dependent signaling pathways that could enhance the function of "BC026682." | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, leading to altered downstream signaling. This could result in compensatory mechanisms or pathway crosstalk that indirectly enhances "BC026682" activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2 leading to decreased ERK phosphorylation. This could shift signaling dynamics to pathways where "BC026682" is involved, potentially enhancing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. The inhibition of this pathway may lead to the activation of alternative pathways, potentially enhancing the activity of "BC026682." | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that could potentiate the activity of "BC026682" by inhibiting competing tyrosine kinase signaling pathways. |